Qure Biotechnology

Qure Biotechnology is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative antibody-based immunotherapies. The company leverages its proprietary platform to engineer multi-specific antibodies that target immune checkpoints and tumor-associated antigens, with a primary focus on the CD47-SIRPα axis. Its lead programs include bispecific antibodies designed to enhance anti-tumor activity while minimizing off-target effects, particularly in gastrointestinal and other solid tumors. Qure Bio operates research and development facilities in both China and the United States to advance its global clinical pipeline. By focusing on synergistic mechanisms of action, the company aims to provide more effective treatments for patients with refractory cancers.